Wiley William Thomas Jr. has reported a significant stock option grant from Canton Strategic Holdings, Inc. This filing, dated October 27, 2026, reveals that Thomas has acquired 53,763 shares through a stock option, a move that underscores the company's strategy to incentivize its board members.

Canton Strategic Holdings, Inc. operates within the finance services sector and is incorporated in Delaware. The company has undergone recent name changes, previously known as Tharimmune, Inc. and Hillstream BioPharma Inc. The current filing indicates that Thomas is a director at Canton Strategic Holdings.

The filing details that the stock option was granted under the company's Amended and Restated 2023 Omnibus Equity Incentive Plan. Of the shares subject to the option, 26,881 shares were vested as of October 23, 2026. An additional 13,441 shares are set to vest on November 1, 2026, with the final 13,441 shares vesting on February 1, 2027, contingent on Thomas's continued service as a board member.

This development may impact the company’s ability to attract and retain top talent, as stock options are a common incentive in the finance services industry. By offering such compensation, Canton Strategic Holdings aims to align the interests of its directors with those of shareholders, potentially enhancing company performance.

Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this stock option grant.